The clinical relevance of micropapillary carcinoma of the breast: A case-control study

Histopathology

Volumn 63, Issue 2, 2013, Pages 217-224

  Vingiani, Andrea ^a   Maisonneuve, Patrick ^a   Dell'Orto, Patrizia ^a   Farante, Gabriel ^a   Rotmensz, Nicole ^a   Lissidini, Germana ^a   Del Castillo, Andres ^a   Renne, Giuseppe ^a   Luini, Alberto ^a   Colleoni, Marco ^a   Viale, Giuseppe ^a,b   Pruneri, Giancarlo ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Micropapillary carcinoma; Survival

Indexed keywords

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROPAPILLARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR INVASION;

EID: 84880735170     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12147     Document Type: Article

References (26)

1. Colleoni M, Rotmensz N, Maisonneuve P et al. Outcome of special types of luminal breast cancer. Ann. Oncol. 2012; 23; 1428-1436.
2. Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 2012; 30; 1879-1887.
3. Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod. Pathol. 1993; 6; 660-662.
4. Yu JI, Choi DH, Park W et al. Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: matched case-control study. Breast 2010; 19; 231-237.
5. Paterakos M, Watkin WG, Edgerton SM et al. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum. Pathol. 1999; 30; 1459-1463.
6. Rosen PP. Rosen's breast pathology. 3rd ed. Philadelphia, PA: Lippincott William & Wilkins, 2008; 616-620.
7. Viale G, Regan MM, Maiorano E et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group. J. Clin. Oncol. 2008; 26; 1404-1410.
8. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 2011; 103; 1656-1664.
9. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
10. Hammond ME, Hayes DF, Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 2010; 6; 195-197.
11. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann. Oncol. 2011; 22; 1736-1747.
12. Marchiò C, Iravani M, Natrajan R et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J. Pathol. 2008; 215; 398-410.
13. Middleton LP, Tressera F, Sobel ME et al. Infiltrating micropapillary carcinoma of the breast. Mod. Pathol. 1999; 12; 499-504.
14. Tresserra F, Grases PJ, Fabregas R et al. Invasive micropapillary carcinoma; distinct features of a poorly recognized variant of breast carcinoma. Eur. J. Gynaecol. Oncol. 1999; 20; 205-208.
15. Luna-Moré S, Casquero S, Pérez-Mellado A et al. Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. Pathol. Res. Pract. 2000; 196; 35-39.
16. Nassar H, Wallis T, Andea A et al. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod. Pathol. 2001; 14; 836-841.
17. Kuroda H, Sakamoto G, Ohnisi K et al. Clinical and pathologic features of invasive micropapillary carcinoma. Breast Cancer 2004; 11; 169-174.
18. Pettinato G, Manivel CJ, Panico L et al. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am. J. Clin. Pathol. 2004; 121; 857-866.
19. Olson EM. Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. J. Clin. Oncol. 2012; 30; 1712-1714.
20. Shelly M, Mosesson Y, Citri A et al. Expression of ErbB-2/HER2 in epithelia: bimodal regulation by Lin-7. Dev. Cell 2003; 5; 75-86.
21. Borg JP, Marchetto S, Le Bivic A et al. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat. Cell Biol. 2000; 2; 407-414.
22. Luna-Moré S, Gonzalez B, Acedo C et al. Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol. Res. Pract. 1994; 190; 668-674.
23. Nassar H, Pansare V, Zhang H et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod. Pathol. 2004; 17; 1045-1050.
24. Rüschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod. Pathol. 2012; 25; 37-50.
25. Owens MA, Horten BC, De Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004; 5; 63-69.
26. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291; 1972-1977.